Showing results (111-120 of 124) with videos related to
Sort By:
Pageof 13
Plos One|November 21, 2023
Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5pShengjuan Lu, Lin Zeng, Guojun Mo, et al.Blood Advances|April 11, 2019
MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphomaHanne Due, Anna Amanda Schönherz, Laura Ryø, et al.Journal of Cell Science|September 10, 2009
Axin2 controls bone remodeling through the beta-catenin-BMP signaling pathway in adult miceYing Yan, Dezhi Tang, Mo Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2013
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistanceZhao Chen, Esra Akbay, Oliver Mikse, et al.Nature Communications|August 12, 2021
Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulationXiaohong Tan, Lu Tong, Lin Li, et al.Human Gene Therapy|July 29, 2017
Selective Antagonism of Bcl-xL Potentiates M1 Oncolysis by Enhancing Mitochondrial ApoptosisYaqian Tan, Yuan Lin, Kai Li, et al.Nature Medicine|November 26, 2008
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersJeffrey A Engelman, Liang Chen, Xiaohong Tan, et al.Cancer Research|October 19, 2010
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogeneZhao Chen, Takaaki Sasaki, Xiaohong Tan, et al.Blood Advances|April 9, 2020
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphomaColm Keane, Soi C Law, Clare Gould, et al.Journal for Immunotherapy of Cancer|October 24, 2019
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapiesZijun Y Xu-Monette, Jianyong Li, Yi Xia, et al.Pageof 13